Support from the Coronavirus Aid, Relief and Economic Security (CARES) Act allowed NCATS to quickly distribute additional funding to tissue chip investigators who proposed applying their work to pressing COVID-19 concerns. Investigators suggested projects to evaluate properties of SARS-CoV-2, the virus that causes COVID-19; the mechanisms of COVID-19 disease pathology; potential COVID-19 therapeutics of known action; and the potential repurposing of approved drugs for use against COVID-19. Rapid distribution of funds was essential for the quick initiation of clinically relevant research contributing to the fight against COVID-19.

Brigham and Women’s Hospital  

Kidney Microphysiological Analysis Platforms (MAP) to Explore SARS‐CoV‐2 Receptors and Inhibitors

Principal Investigator: Joseph Vincent Bonventre, M.D., Ph.D.  
Grant Number: 3-UH3-TR-002155-04S1

Cedars-Sinai Medical Center  

A Lung‐Chip Microphysiological System to Model SARS‐CoV‐2 Infection and Test Novel Therapeutics

Principal Investigator: Clive Niels Svendsen, Ph.D.  
Grant Number: 3-UG3-NS-105703-03S1

Duke University  

Vascular, Cardiac and Lung Alveolar Human Microphysiological Systems for SARS-COV-2 Drug Screening

Principal Investigator: George A. Truskey, Ph.D.  
Grant Number: 3-UH3-TR-002142-04S1

Harvard University  

Lung-on-a-Chip Disease Models for Efficacy Testing

Principal Investigator: Donald E. Ingber, M.D., Ph.D.  
Grant Number: 3-UH3-HL-141797‐04S1

Massachusetts Institute of Technology   

Construction of an Integrated Immune-Vascular Brain-Chip as a Platform for the Study, Drug Screening and Treatments of Alzheimer’s Disease

Principal Investigator: Li-Huei Tsai, Ph.D.  
Grant Number: 3-UG3-NS-115064-01S1

Montana State University, Bozeman  

Using the GoFlowChip to Understand SARS-CoV-2 Infection of the Gastrointestinal Mucosa of Humans and Bats

Principal Investigator: Seth T. Walk, Ph.D.  
Grant Number: 3-U01-EB-029242‐02S1

Nortis, Inc.    

Organ‐on‐Chip Approach for Assessing Tissue‐Specific SARS‐CoV‐2 Infection and Response to Antiviral Therapy

Principal Investigator: Thomas Neumann, M.D.  
Grant Number: 3-R44-TR-003065-02S1

University of California, Davis  

A 3-D In Vitro Disease Model of Atrial Conduction

Principal Investigator: Steven Carl George, M.D., Ph.D.  
Grant Number: 3-UH3-HL-141800-04S1

University of California, Irvine  

Microphysiological Systems to Model Vascular Malformations

Principal Investigator: Christopher C. W. Hughes, Ph.D.  
Grant Number: 3-UH3-HL-141799-04S1

University of Pittsburgh  

Therapeutic Strategies to Test the Mitigation of the Cytokine Storm Syndrome and Coagulopathy in Patient Cell‐Derived vLAMPS with Diabetes and COVID-19 Infection

Principal Investigator: Lansing D. Taylor, Ph.D.  
Grant Number: 3-UH3-DK-119973-03S1

University of Washington

Cellular and Molecular Mechanisms of COVID-19 Mediated Kidney Injury

Principal Investigator: Jonathan Himmelfarb, M.D.  
Grant Number: 3-UH3-TR-002158-04S1

Vanderbilt University  

Drug Development for Tuberous Sclerosis Complex and Other Pediatric Epileptogenic Diseases Using Neurovascular and Cardiac Microphysiological 

Principal Investigator: John Peter Wikswo, Ph.D.  
Grant Number: 3-UH3-TR-002097-04S1